Volume 3, Issue 4 | November 2016
Case Report | Esophagus

Metastatic Esophageal Cancer Presenting as an Orbital Mass

Download PDF

Sunil Pokharel, MD1, Ghassan Kabbach, MD, MSc1, Seth J. Richter, MD2, and Laura Chiu, MD3

1Department of Medicine, Albany Medical College, Albany, NY
2Division of Gastroenterology, Albany Medical College, Albany, NY
3Albany Medical College, Albany, NY

ACG Case Rep J 2016;3(4):e154. http://dx.doi.org/10.14309/crj.2016.127. Published online: November 23, 2016.

Abstract

We report a case of adenocarcinoma of the esophagus presenting as an orbital metastasis prior to the primary diagnosis. A 66-year-old white male presented to his ophthalmologist with right orbital swelling for several months. Magnetic resonance imaging revealed a supraorbital infiltrative mass. Pathology from the mass revealed findings consistent with adenocarcinoma of gastrointestinal origin. Upper endoscopy revealed distal esophageal stricture and irregularities. Pathology from the esophagus showed the same malignancy found in the orbit. An orbital swelling can manifest as the initial presentation of metastatic disease and should be taken seriously to avoid delay in diagnosis and treatment.


Introduction

Malignant orbital masses occur rarely. The 3 most common primary sites to metastasize to the orbit are prostate, breast, and lung.1,2 A recent large retrospective series identified that the rate of orbital metastasis was 3%.1 Orbital masses are usually slow growing and are often followed up as an outpatient; in certain circumstances, however, they can manifest as the first sign of systemic illness. In as many as 19% of the cases, these are the only manifestation of underlying malignancies and can easily be overlooked.3,4


Case Report

A 66-year-old male was sent to our emergency department by his ophthalmologist for the evaluation of a right orbital mass and proptosis. On follow-up at 3 months, magnetic resonance imaging showed an infiltrative mass on the right supraorbital region with mass effect on the patient’s right globe (Figure 1).

CG-CGCR160080F001

Figure 1. Brain magnetic resonance imaging (T2W) showing a heterogeneous infiltrative mass (arrow) within the right superior orbit measuring approximately 3.3 x 3.9 x 2.0 cm.

The patient did not have any visual complaints but had noticed swelling for the last 3 months, which had progressively worsened. He also complained of mild dysphagia with nearly 18-kg weight loss in 3 months. He underwent right orbitotomy and resection of the orbital mass. Immunohistochemical staining performed on the tumor cells was positive for CK7, MUC5AC, and ARG2 and negative for CK5/6, P63, Napsin A, and TTF1, suggesting adenocarcinoma of upper gastrointestinal origin (Figure 2).

CG-CGCR160080F002

Figure 2. Orbital mass biopsy showing histomorphology consistent with adenocarcinoma of gastrointestinal origin (hematoxylin and eosin staining, 200x).

Chest, abdominal, and pelvic computed tomography revealed irregular and thickened distal esophageal tissue. The patient then underwent upper endoscopy, which revealed stricture of the distal esophagus, from which multiple biopsies were taken (Figure 3). The biopsy revealed the same malignancy, which confirmed that the mass was poorly differentiated esophageal adenocarcinoma (Figure 4).

CG-CGCR160080F003

Figure 3. Upper endoscopy showing distal esophageal stricture.

Chest and abdominal computed tomography and brain magnetic resonance imaging showed no other metastases. This was later confirmed with positron emission tomography, which showed uptake in the right orbit apart from the esophagus. The patient underwent placement of an esophageal stent for dysphagia and was discharged home with outpatient follow up with oncology. Positron emission tomography was planned as an outpatient.

CG-CGCR160080F004

Figure 4. Esophageal biopsy showing a single nest of tumor cells in a background of intestinalized metaplastic epithelium (hematoxylin and eosin staining, 80x).


Discussion

Orbital swelling and proptosis are the most common manifestations of primary eye malignancy.3,4 The incidence of an isolated orbital lesion being a metastatic disease is rare.2,5,6 In one of the largest reported series of orbital tumors, metastases accounted for 7% of the total orbital tumors in adults.1,2 Of these, the most common primary sites were breast and prostate, accounting for 48% and 12% of the total orbital metastases, respectively.1,2 Esophageal and urothelial carcinoma metastases to the orbit have been reported, but they occurred at a much lower frequency.5,6 Upon our review of the literature we found very few reported cases of esophageal carcinoma with metastasis to the orbit.2,5-7 The typical presentation is with a mass lesion causing proptosis or an ocular motility defect.4,6 There have been some reported cases of orbital metastases that present as orbital cellulitis or abscess.1

Survival after diagnosis of orbital metastases ranges from 13 months to 1.5 years, with variation due to histologic type.8-10 For instance, orbital carcinoid metastases appears to have a median survival of 24 months in one series.11 No well-defined treatment modality exists for orbital metastasis. Options include radiotherapy, chemotherapy, hormone therapy, surgery, and immunotherapy.10 For example, neuroendocrine tumors metastatic to the orbit can be treated with stereotactic radiotherapy,12 radiolabeled octreotide, or with peptide-receptor radiolabeled therapy using 177Lu-DOTATATE.13


Disclosures

Author contributions: S. Pokharel wrote the manuscript and is the article guarantor. SJ Richter reviewed and edited the manuscript. G. Kabbach edited the manuscript and obtained the figures. L. Chiu obtained endoscopy slides.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Correspondence: Sunil Pokharel, Department of Medicine, Albany Medical College, 47 New Scotland Ave, Mail Code 17, Albany, NY 12208 (pokhars@mail.amc.edu).

Received September 28, 2015; Accepted April 18, 2016


References

  1. George NM, Charles MP, Wade AR, et al. Esophageal adenocarcinoma and urothelial carcinoma orbital metastases masquerading as infection. Orbit. 2015;34(1):51–5. Article | PubMed
  2. Bonavolonta G, Strianese D, Grassi P, et al. An analysis of 2,480 space occupying lesions of the orbit from 1976 to 2011. Ophthal Plast Reconstruct Surg. 2013;29(2):79–86. Article | PubMed
  3. Aralikatti DA, Nylander AG. Orbital metastasis from squamous cell carcinoma of the esophagus. Eur J Ophthalmol. 2006;16(3):458–60. PubMed
  4. Marinkovic M, van Lanschot JJ, Schlingemann RO, et al. Eye complaints indicative of a tumor elsewhere in the body [in Dutch]. Ned Tijdschr Geneeskd. 2002;146(50):2393–6. PubMed
  5. Ng E, Ilsen PF. Orbital metastases. Optometry. 2010;81(12):647–57. Article | PubMed
  6. Lee JY, Lee HJ, Jung MS, Kim SY. Metastatic esophageal squamous cell carcinoma to the orbit and periorbit masquerading as periorbital abscess. Korean J Ophthalmol. 2010;24(2):123–5. Article | PubMed
  7. Collins MJ, Wojno TH, Grossniklaus HE. Metastatic esophageal carcinoma to the orbit. Ophthalmol. 1999;127(2):228–9. PubMed
  8. Shields CL, Shields JA, Peggs M. Tumors metastatic to the orbit. Ophthal Plast Reconstr Surg. 1988;4(2):73–80. PubMed
  9. Magliozzi P, Strianese D, Bonavolontà P, et al. Orbital metastases in Italy. 2015;8(5):1018–23. Article | PubMed
  10. Valenzuela AA, Archibald CW, Fleming B, et al. Orbital metastasis: Clinical features, management and outcome. Orbit. 2009;28(2-3):153–9. PubMed
  11. Mehta JS, Abou-Rayyah Y, Rose GE. Orbital carcinoid metastases. Ophthalmology. 2006;113(3):466–72. Article | PubMed
  12. Peixoto RD, Lim HJ, Cheung WY. Neuroendocrine tumor metastatic to the orbit treated with radiotherapy. World J Gastrointest Oncol. 2013;5(8):177–80. Article | PubMed
  13. Dobson R, Vinjamuri S, Hsuan J, et al. Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE. J Clin Oncol. 2013;31(17):e272–5. Article | PubMed

CC Icon

© 2016 Pokharel et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.